TrialHematological oncology2026

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).

Francesco Passamonti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.